Prestigious Researchers to Provide Consulting Services in Connection with ABVC BioPharma's Depression Medicines
23. Mai 2022 07:30 ET
|
ABVC BioPharma, Inc.
Fremont, CA, May 23, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in...
ABVC Biopharma Reports First Quarter 2022 Financial and Operational Results
16. Mai 2022 17:46 ET
|
ABVC BioPharma, Inc.
FREMONT, CA, May 16, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire--ABVC BioPharma, Inc. (Nasdaq: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in...
ABVC BioPharma Engages the FreeMind Group to Support Grant Funding
13. Mai 2022 08:30 ET
|
ABVC BioPharma, Inc.
FREMONT, CA, May 13, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in...
ABVC BioPharma, Inc. Announces $4.22 Million Registered Direct Offering
12. Mai 2022 08:30 ET
|
ABVC BioPharma, Inc.
Fremont, CA, May 12, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- ABVC BioPharma, Inc. (“ABVC” or the “Company”) (NASDAQ: ABVC) today announced that it has entered into securities purchase...
ABVC BioPharma ADHD Phase II Part 2 Clinical Study First Subject Treated
10. Mai 2022 08:30 ET
|
ABVC BioPharma, Inc.
FREMONT, CA, May 10, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC Biopharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in...
ABVC BioPharma Announces Streamlined Vitargus® Manufacturing Process
05. Mai 2022 08:30 ET
|
ABVC BioPharma, Inc.
New Process Improves Quality and Lowers Cost Fremont, CA, May 05, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- ABVC BioPharma, Inc. (NASDAQ:ABVC), a clinical stage biopharmaceutical company...
ABVC BioPharma Enters Into $3.0 Million Clinical Services Contract with NeuCen BioMed
03. Mai 2022 08:30 ET
|
ABVC BioPharma, Inc.
FREMONT, CA, May 03, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC Biopharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in...
ABVC BioPharma Completes Site Initiation Visits and Begins Enrollments for ADHD Phase II Part 2 Clinical Study
28. April 2022 08:30 ET
|
ABVC BioPharma, Inc.
FREMONT, CA, April 28, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire - ABVC Biopharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in...
ABVC BioPharma Announces Vitargus Phase II Clinical Study Investigator Meeting
26. April 2022 08:30 ET
|
ABVC BioPharma, Inc.
FREMONT, CA, April 26, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in...
ABVC Biopharma Announces Fiscal Year 2021 Financial and Operational Results
31. März 2022 16:18 ET
|
ABVC BioPharma, Inc.
FREMONT, CA, March 31, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- ABVC BioPharma, Inc. (Nasdaq: ABVC), a biotechnology company specializing in botanically based solutions that seeks to deliver...